We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, ANI Pharmaceuticals (ANIP - Free Report) closed at $69.44, marking a +1.71% move from the previous day. This move outpaced the S&P 500's daily gain of 0.66%. Meanwhile, the Dow gained 1.03%, and the Nasdaq, a tech-heavy index, added 0.46%.
Prior to today's trading, shares of the drugmaker had gained 7.11% over the past month. This has outpaced the Medical sector's loss of 0.8% and the S&P 500's gain of 3.97% in that time.
Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. On that day, ANIP is projected to report earnings of $1.03 per share, which would represent a year-over-year decline of 21.97%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ANIP. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.92% higher. ANIP currently has a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, ANIP is holding a Forward P/E ratio of 11.44. Its industry sports an average Forward P/E of 21.91, so we one might conclude that ANIP is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, ANI Pharmaceuticals (ANIP - Free Report) closed at $69.44, marking a +1.71% move from the previous day. This move outpaced the S&P 500's daily gain of 0.66%. Meanwhile, the Dow gained 1.03%, and the Nasdaq, a tech-heavy index, added 0.46%.
Prior to today's trading, shares of the drugmaker had gained 7.11% over the past month. This has outpaced the Medical sector's loss of 0.8% and the S&P 500's gain of 3.97% in that time.
Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. On that day, ANIP is projected to report earnings of $1.03 per share, which would represent a year-over-year decline of 21.97%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ANIP. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.92% higher. ANIP currently has a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, ANIP is holding a Forward P/E ratio of 11.44. Its industry sports an average Forward P/E of 21.91, so we one might conclude that ANIP is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.